New hope for hodgkin lymphoma: drug showdown in phase 3 trial
NCT ID NCT02684292
First seen Jan 07, 2026 · Last updated Apr 24, 2026 · Updated 15 times
Summary
This study tested two drugs, pembrolizumab and brentuximab vedotin, in 304 people whose Hodgkin lymphoma had returned or not responded to prior therapy. The goal was to see which drug better delays cancer growth and extends life. Participants received treatment for up to 35 three-week cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.